<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9972">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05686317</url>
  </required_header>
  <id_info>
    <org_study_id>2022-06</org_study_id>
    <nct_id>NCT05686317</nct_id>
  </id_info>
  <brief_title>ALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt System</brief_title>
  <acronym>ALT-FLOW II</acronym>
  <official_title>A Randomized, Sham-controlled Trial of the Edwards APTURE Transcatheter Shunt System (ALT-FLOW II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-center, randomized, sham-controlled clinical trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of this trial are to assess the safety, performance, and effectiveness of the&#xD;
      Edwards APTURE transcatheter shunt system when used for the treatment of patients with heart&#xD;
      failure with preserved (HFpEF) or mildly reduced (HFmrEF) ejection fraction (LVEF &gt;40%)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2023</start_date>
  <completion_date type="Anticipated">October 31, 2030</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Device + Medical Therapy: Subjects with Early Major Adverse Events</measure>
    <time_frame>30 days</time_frame>
    <description>Shunt implant safety: proportion of patients in the APTURE shunt group without any serious device or procedure-related (CEC adjudicated) complications (i.e., Major Adverse Cardiovascular, Cerebrovascular, and Renal Events [MACCRE]; at 30 days post index procedure or hospital discharge, whichever is later.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change in PCWP from baseline at 20W exercise</measure>
    <time_frame>6-months</time_frame>
    <description>Hemodynamic Effectiveness: change in PCWP at 20W exercise from baseline (mmHg) at 6 months.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>APTURE shunt + medical therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham + medical therapy</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Edwards APTURE transcatheter shunt system</intervention_name>
    <description>Treatment with APTURE shunt</description>
    <arm_group_label>APTURE shunt + medical therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Sham procedure</intervention_name>
    <description>CS angiography</description>
    <arm_group_label>Sham + medical therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Symptomatic heart failure&#xD;
&#xD;
               -  A primary diagnosis of HFmrEF or HFpEF (LVEF &gt; 40%), and&#xD;
&#xD;
               -  NYHA class II to ambulatory NYHA class IV, and&#xD;
&#xD;
          -  Documentation of the following within 6 months:&#xD;
&#xD;
               -  ≥ 1 prior HF hospitalization(s)* (with HF as the primary or secondary diagnosis);&#xD;
                  OR&#xD;
&#xD;
               -  ≥ 1 prior HF events(s)*, ORBNP value &gt; 50 pg/ml in normal sinus rhythm (NSR) or &gt;&#xD;
                  150 pg/ml in atrial fibrillation; OR&#xD;
&#xD;
               -  NT-proBNP &gt; 150 pg /ml in NSR or &gt; 450 pg /ml in atrial fibrillation&#xD;
&#xD;
          -  Hemodynamic criteria assessed by right heart catheterization (RHC) and confirmed by&#xD;
             site cardiologist:&#xD;
&#xD;
               -  Mean right atrial pressure (mRAP) &lt; 18 mmHg on RHC&#xD;
&#xD;
               -  Pulmonary capillary wedge pressure (PCWP) as measured at end-expiration, during&#xD;
                  at least one exercise stage of the supine ergometer exercise stress test:&#xD;
&#xD;
                    -  PCWP elevated to &gt;25 mmHg, AND&#xD;
&#xD;
                    -  PCWP exceeds RAP by ≥ 10 mmHg&#xD;
&#xD;
               -  Resting pulmonary vascular resistance (PVR) &lt; 5.0 WU&#xD;
&#xD;
          -  In the judgment of the treating physician and the Central Screening Committee (CSC)&#xD;
             and according to current 2022AHA/ACC/HFSA Guidelines, the patient is on stable medical&#xD;
             therapy for HFpEF/HFmrEF that is expected to be maintained without change for 6&#xD;
             months.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Severe heart failure defined as one or more of the below:&#xD;
&#xD;
               -  ACC/AHA/ESC Stage D HF, non-ambulatory NYHA Class IV HF&#xD;
&#xD;
               -  If Body Mass Index (BMI) &lt; 30, cardiac index &lt; 2.0 L/min/m2&#xD;
&#xD;
               -  If BMI ≥ 30, cardiac index &lt; 1.8 L/min/m2&#xD;
&#xD;
               -  Inotropic infusion (continuous or intermittent) within the past 6 months&#xD;
&#xD;
               -  Patient is on the cardiac transplant waiting list&#xD;
&#xD;
               -  Left ventricular ejection fraction (LVEF) ≤ 40%&#xD;
&#xD;
          -  Valve disease:&#xD;
&#xD;
               -  Degenerative mitral regurgitation &gt; moderate&#xD;
&#xD;
               -  Functional or secondary mitral valve regurgitation defined as grade &gt; 2+ MR&#xD;
&#xD;
               -  Mitral stenosis &gt; Mild&#xD;
&#xD;
               -  Primary or secondary tricuspid valve regurgitation defined as grade &gt; 2+ TR&#xD;
&#xD;
               -  Aortic valve disease defined as &gt; 2+ AR or &gt; moderate AS&#xD;
&#xD;
          -  Right ventricular dysfunction:&#xD;
&#xD;
               -  More than mild RV dysfunction; OR&#xD;
&#xD;
               -  RV size ≥ LV size&#xD;
&#xD;
               -  Right ventricular ejection fraction (RVEF) &lt; 35%; OR&#xD;
&#xD;
               -  Imaging or clinical evidence of congestive hepatopathy&#xD;
&#xD;
          -  Myocardial infarction (MI) and/or any therapeutic invasive, non-valvular&#xD;
             cardiovascular procedure within past 3 months or current indication for coronary&#xD;
             revascularization&#xD;
&#xD;
          -  Stroke, transient ischemic attack (TIA), deep vein thrombosis (DVT) or pulmonary&#xD;
             embolus within the past 6 months&#xD;
&#xD;
          -  Renal insufficiency as determined by creatinine (sCr) level &gt; 2.5 mg/dL or estimated&#xD;
             glomerular filtration rate (eGFR) &lt; 25ml/min/1.73 m2 by CKD-Epi equation; or currently&#xD;
             requiring dialysis&#xD;
&#xD;
          -  Performance of the six-minute walk test (6MWT) with a distance &lt; 50m OR &gt; 450m&#xD;
&#xD;
          -  Active endocarditis or infection requiring intravenous antibiotics within 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bridget Hurley</last_name>
    <phone>(949) 250-2265</phone>
    <email>bridget_hurley@edwards.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Melissa Arteaga</last_name>
    <phone>(949) 250-2002</phone>
    <email>melissa_arteaga@edwards.com</email>
  </overall_contact_backup>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>January 6, 2023</study_first_submitted>
  <study_first_submitted_qc>January 6, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2023</study_first_posted>
  <last_update_submitted>March 7, 2023</last_update_submitted>
  <last_update_submitted_qc>March 7, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

